SXSophia Xiao

Sophia Xiao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sophia Xiao has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perioperative Risks of Concurrent Pancreatic and Hepatic Resections for Neuroendocrine Tumors

    by Amir Ebadinejad, Ashrita Raghuram, Sophia Xiao, Ethan Angle, Hassan Aziz

    Background and Objectives: Pancreatic neuroendocrine tumors (pNETs) account for 1%–2% of pancreatic tumors, with an increasing incidence. The safety of concurrent pancreas‐liver resections remains uncertain. This study evaluated the national outcomes of concurrent pancreatectomy and liver‐directed surgery for pNETs. Methods: ACS‐NSQIP (2019–2023) was queried for adult patients who underwent pancreatectomy for pNETs. Concurrent liver‐directed procedures were identified by CPT code and classified as hepatectomy or ablation alone; patients were grouped as isolated pancreatectomy, concurrent hepatectomy, or concurrent ablation alone. Pre‐, intra‐, and postoperative characteristics were compared using inferential statistics. Multivariable logistic regression identified predictors of 30‐day morbidity, readmission, reoperation, and mortality, with Firth penalized likelihood used for rare outcomes. Results: Of 4794 patients, 4587 (95.7%) underwent isolated pancreatectomy, 172 (3.6%) underwent concurrent hepatectomy, and 35 (0.7%) underwent concurrent ablation alone. Concurrent hepatectomy was parenchymal‐sparing in 163 of 172 patients (94.8%); only nine patients underwent a major hepatectomy. Overall morbidity was similar across groups (38.8%, 45.9%, and 42.9%; p = 0.154), as was serious morbidity (28.7%, 27.9%, 22.9%; p = 0.730) and 30‐day mortality (1.0%, 0.6%, 0%). On multivariable analysis, neither concurrent hepatectomy (OR 1.02, 95% CI 0.71–1.48) nor concurrent ablation (OR 0.94, 95% CI 0.46–1.93) was associated with morbidity. Pancreatoduodenectomy was associated with morbidity (OR 2.38, 95% CI 2.05–2.76), reoperation (OR 2.16, 95% CI 1.52–3.08), and mortality (OR 2.50, 95% CI 1.39–4.50), and a minimally invasive approach was associated with lower morbidity (OR 0.69, 95% CI 0.60–0.80). Conclusions: Concurrent liver‐directed surgery was not associated with an increase in 30‐day morbidity or mortality after pancreatectomy for pNETs. These findings support the safety of concurrent hepatic resection in appropriately selected pNET patients.

  • Open Access

    Course of Carpal Tunnel Syndrome Management in Patients With Diabetes

    by Sophia Xiao, Ignacio Garcia Fleury, Natalie Glass, Joseph Buckwalter

    Background: Carpal Tunnel Syndrome (CTS) is the most prevalent compressive neuropathy, often worsened by microvasculopathy in diabetic neuropathy. Diabetes mellitus (DM) patients experience increased CTS risk but are frequently underdiagnosed. This study investigates the progression to CTS diagnosis and CT release (CTR) in DM patients, aimed at better early detection and CTS prevention. Methods: Data including age and HbA1c from 304 patients with CTS, DM, and CTR (2012–2022) was collected from a tertiary care center. CTS–CTR time was compared between patients diagnosed with DM pre‐ or post‐CTS using Wilcoxon rank‐sum tests. Analyses were conducted using SAS v9.4. Relationships between age or HbA1c and CTS–CTR or DM–CTS timelines were described by Spearman correlation coefficients. Results: 51% ( n = 154) of patients received DM diagnosis post‐CTS identification. Time between diagnoses was similar in patients diagnosed with DM before vs. after CTS (24.6 (8.0–41.8), 24.3 (9.9–46.2) months, p = 0.604). From CTS to first CTR, the median time difference was 2.5 months (1.0–8.1) with no significant impact from DM diagnosis timing (before: 2.57, after: 2.20 months, p = 0.188). CTS–CTR time correlated with age ( = −0.24, p < 0.001) and HbA1c (=−0.15, p = 0.002) at CTS diagnosis. No associations occurred with age or HbA1c at DM diagnosis (age: = 0.03, p = 0.660, HbA1c: = 0.00, p = 1.00). Conclusions: Over half of CTR patients were diagnosed with DM before CTS, underscoring the urgency for assessing new DM patients for CTS symptoms. Future clinical programs should target early identification of CTS signs and optimal timing for surgical interventions to enhance patient well‐being.